ID: ALA4537350

Max Phase: Preclinical

Molecular Formula: C17H8Cl3FO3S

Molecular Weight: 417.67

Molecule Type: Unknown

Representations

Canonical SMILES:  O=C(c1ccc(-c2cc(Cl)c(O)c(Cl)c2)s1)c1c(Cl)ccc(O)c1F

Standard InChI:  InChI=1S/C17H8Cl3FO3S/c18-8-1-2-11(22)15(21)14(8)17(24)13-4-3-12(25-13)7-5-9(19)16(23)10(20)6-7/h1-6,22-23H

Standard InChI Key:  MNBRTTWYOOWKCW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 417.67

Molecular Weight (Monoisotopic): 415.9244

AlogP: 6.16

#Rotatable Bonds: 3

Polar Surface Area: 57.53

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 6.06

CX Basic pKa:

CX LogP: 6.34

CX LogD: 4.82

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.50

Np Likeness Score: -0.59

References

1. Abdelsamie AS, Salah M, Siebenbürger L, Hamed MM, Börger C, van Koppen CJ, Frotscher M, Hartmann RW..  (2019)  Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.,  178  [PMID:31176098] [10.1016/j.ejmech.2019.05.084]

Source

Source(1):

• Scientific Literature